TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00859898
Drug: Metformin XR
Normalized name: metformin Extended Release Suspension
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablets, Oral, 500 mg up to 2000 mg, once daily 24 weeks
Study: NCT00859898
Drug: dapagliflozin matching Placebo
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tablets
Study: NCT00859898
Drug: metformin HCl Modified Release matching Placebo
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablets
Study: NCT04181203
Drug: Apalutamide
Normalized name: Apalutamide
DrugBank: Apalutamide (DB11901)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 240 mg PO daily should start the same day as the first LHRHa administration for 6 months.~months.
Study: NCT04181203
Drug: Luteinising Hormone Releasing Hormone agonist (LHRHa)
DrugBank: Lutein (DB00137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doses of LHRHa may vary due to availability of different brand names and pharmaceutical forms. It will be left to the discretion of the investigator.
Study: NCT00602862
Drug: Sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sorafenib 200 mg 2dd2 po for 4 weeks before surgery
Study: NCT00602862
Drug: 111Indium-bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 100 MBq / 1 mg 111Indium/bevacizumab iv
Study: NCT00602862
Drug: 111Indium-cG250
Normalized name: 111Indium pentetreotide
DrugBank: Indium (DB11659)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 MBq / 10 mg 111Indium-cG250 iv
Study: NCT00239200
Drug: Lapatinib
Normalized name: Lapatinib
DrugBank: Lapatinib (DB01259)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03630640
Drug: Nivolumab Injection [Opdivo]
Normalized name: nivolumab Injection [Opdivo]
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous Nivolumab 240 Q2W neoadjuvant Intravenous Nivolumab 480 mg Q4W- adjuvant up to 12 months after EP
Study: NCT01380496
Drug: doxycycline monohydrate
Normalized name: Doxycycline Monohydrate
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tablet, 100 mg, single, oral dose
Study: NCT01380496
Drug: doxycycline monohydrate
Normalized name: Doxycycline Monohydrate
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsule, 100 mg, single, oral dose
Study: NCT00408993
Drug: Duloxetine Hydrochloride
Normalized name: Duloxetine Hydrochloride
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60 mg every day (QD) (morning or evening), by mouth (PO)
Study: NCT02696850
Drug: Budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will undergo 4-week treatment course that includes budesonide powder added to saline rinse.
Study: NCT03738865
Drug: Novo Glucagon
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1 mg subcutaneous injection of Novo Glucagon (glucagon injection)
Study: NCT01146938
Drug: fimasartan
Normalized name: Fimasartan
DrugBank: Fimasartan (DB09279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single administration of fimasartan 120mg
Study: NCT02692248
Drug: Ibrutinib
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ibrutinib 560 mg daily for 14 days during induction cycles. Maintenance phase: Continuous cycles until disease progression or unacceptable toxicity (maximum of 2 years).
Study: NCT02692248
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab 375 mg/m2 IV day 1 during 4 cycles.
Study: NCT01176851
Drug: Glycopyrrolate
Normalized name: Glycopyrrolate
DrugBank: Glycopyrronium (DB00986)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single administration of Glyco pMDI 100 µg
Study: NCT02692248
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine 1000 mg/m2 IV (30-minute infusion) on day 1 or 2, 4 cycles every 14 days.
Study: NCT02692248
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin 100 mg/m2 (3-hour infusion) on day 1 or 2, after Gemcitabine infusion, 4 cycles every 14 days.
Study: NCT02692248
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone 20 mg orally or IV on day 1 and orally on days 2-3, 4 cycles every 14 days.
Study: NCT01176851
Drug: Glycopyrrolate
Normalized name: Glycopyrrolate
DrugBank: Glycopyrronium (DB00986)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single administration of Glyco pMDI 100 µg after charcoal ingestion
Study: NCT01176851
Drug: Glycopyrrolate
Normalized name: Glycopyrrolate
DrugBank: Glycopyrronium (DB00986)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous injection of glycopyrrolate 100 µg
Study: NCT00382343
Drug: Sulfamethoxazole/trimethoprim
Normalized name: SULFAMETHOXAZOLE/TRIMETHOPRIM
DrugBank: Trimethoprim (DB00440)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulfamethoxazole/trimethoprim prophylaxis
Study: NCT02580149
Drug: Ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive an oral loading dose of 180 mg ticagrelor on study day~1 followed by a maintenance dose of 90 mg twice daily for 14 days (until study day 15).
Study: NCT02580149
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subjects will receive a loading dose of 600 mg clopidogrel on the first study day followed by a maintenance dose of 75 mg once daily for 14 days
Study: NCT03574792
Drug: Gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT03574792
Drug: Methadone
Normalized name: Methadone
DrugBank: Methadone (DB00333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT03574792
Drug: Oxycodone
Normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT03574792
Drug: Venlafaxine
Normalized name: Venlafaxine
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT03574792
Drug: Venlafaxine Hydrochloride Extended Release
Normalized name: venlafaxine Extended Release Oral Capsule
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT02488486
Drug: propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00741234
Drug: SB939
Normalized name: Panobinostat
DrugBank: Panobinostat (DB06603)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: SB939 taken orally in a 4-week cycle.
Study: NCT00741234
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azacitidine taken orally with SB939 in a 4-week cycle
Study: NCT02998242
Drug: Apatinib
Normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00581945
Drug: Canakinumab
Normalized name: Canakinumab
DrugBank: Canakinumab (DB06168)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The dose of canakinumab (ACZ885) administered was individualized, based on the subject's weight pre-dose, and was administered via intravenous infusion.
Study: NCT00326235
Drug: Buspirone
Normalized name: Buspirone
DrugBank: Buspirone (DB00490)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02669030
Drug: suvorexant
Normalized name: Suvorexant
DrugBank: Suvorexant (DB09034)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: an FDA-approved sleep aid
Study: NCT03335553
Drug: BMS-986235
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Specified dose on specified days
Study: NCT01413451
Drug: Amatuximab (MORab-009)
Normalized name: Isatuximab
DrugBank: Amatuximab (DB12845)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03048084
Drug: Levetiracetam
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Antiepileptic drug levetiracetam
Study: NCT03048084
Drug: Valproic Acid
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antiepileptic drug valproic acid
Study: NCT02048761
Drug: 1 % Metformin gel
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: After debridement, 1% Metformin gel gel was applied into the periodontal pockets with a syringe and a blunt canula.
Study: NCT00767000
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin ≥1500 mg/day at a stable dose for at least 6 weeks before Screening and for the duration of the study. The number of randomized participants who receive metformin will be capped at 70% of enrollment.
Study: NCT02032901
Drug: Daclatasvir
Normalized name: Daclatasvir
DrugBank: Daclatasvir (DB09102)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02032901
Drug: Sofosbuvir
Normalized name: Sofosbuvir
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03212274
Drug: Olaparib
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT03502343
Drug: Modified Gemcitabine plus nab-Paclitaxel Combination Chemotherapy
Normalized name: Paclitaxel
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: All patients will receive slow (over 30-40 minutes) intravenous administration of nab-paclitaxel (125 mg/m2) on days 1 and 15, and gemcitabine (1000 mg/m2) on days 1, 8, and 15 of a 28- day cycle (every 4 weeks). Treatment will discontinue if disease progression or intolerable toxicity is observed, if the patient withdraws from the study, or at the physician's discretion.~Dose reduction of the chemotherapeutic agent and/or delay of administration is allowed if serious treatment-related AEs occur, according to specified guideline in study protocol (Level 1: 100% -\> 80%; Level 2: 80% -\> 60%). If dose reduction is needed more than Level 2, the patient will be dropped from the trial.
Study: NCT01194115
Drug: cephalexin & metronidazole
DrugBank: Cephalexin (DB00567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: cephalexin at 500 mg per oral every 8 hours for a total of 6 doses
Study: NCT00692939
Drug: Alemtuzumab
Normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Transplant conditioning
Study: NCT00692939
Drug: ATG
Normalized name: eATG
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transplant conditioning
Study: NCT00692939
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transplant conditioning
Study: NCT00692939
Drug: Thiotepa
Normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Transplant conditioning
Study: NCT00126451
Drug: MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA)
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00957346
Drug: Mifepristone+misoprostol
DrugBank: Mifepristone (DB00834)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single dose of 200 mg mifepristone followed 24 hours later by 400 mcg misoprostol administered buccally and repeated every 3 hours for a maximum of 5 doses.
Study: NCT00957346
Drug: Placebo+Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: placebo resembling mifepristone followed 24 hours later by 400 mcg buccal misoprostol repeated every 3 hours until complete abortion or maximum of 5 doses.
Study: NCT03807999
Drug: Nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03807999
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT05775692
Drug: fluconazole
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: According to the models of population pharmacokinetics,the investigators and want to correlate use of fluconazole with treatment effectiveness and safety in newborns
Study: NCT00692939
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Transplant conditioning
Study: NCT00692939
Drug: G-CSF
Normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Mobilization
Study: NCT00692939
Drug: Mesna
Normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mobilization
Study: NCT02833831
Drug: ALS-008176
Normalized name: ALS-008176
DrugBank: Lumicitabine (DB14808)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single dose of ALS-008176 orally.
Study: NCT02833831
Drug: Moxifloxacin
Normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive a single dose of moxifloxacin 400 mg.
Study: NCT00949247
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. After 6 courses, treatment modifications may apply according to response.
Study: NCT00949247
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. After 6 courses, treatment modifications may apply according to response.
Study: NCT03869073
Drug: Evolocumab
Normalized name: Evolocumab
DrugBank: Evolocumab (DB09303)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Three pre-filled shrouded syringes for subcutaneous injection in abdomen.
Study: NCT00425438
Drug: Mycophenolate Mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 0.5 g PO BID from Day 0 to the end of Week 1, followed by 1.0 g PO BID from Weeks 2 through 24, and 0.75 g PO BID from Weeks 32 to 48
Study: NCT00788840
Drug: Insulatard
Normalized name: Pork Insulatard
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulatard insulin used as long-acting insulin for 16-week treatment phase of study.
Study: NCT00788840
Drug: Detemir
Normalized name: Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Detemir insulin used as long-acting insulin in treatment phase of study.
Study: NCT04594694
Drug: Obeticholic acid
Normalized name: Obeticholic acid
DrugBank: Obeticholic acid (DB05990)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 5 mg tablet of OCA once daily titrating up to a maximum of 10 mg OCA once daily
Study: NCT04594694
Drug: Bezafibrate 200 MG
Normalized name: bezafibrate 200 MG
DrugBank: Bezafibrate (DB01393)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg IR tablet of Bezafibrate once daily for the remainder of the study
Study: NCT04594694
Drug: Bezafibrate 200 mg Placebo
Normalized name: bezafibrate 200 MG
DrugBank: Bezafibrate (DB01393)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet daily for the remainder of the study
Study: NCT04594694
Drug: Bezafibrate 400 MG
Normalized name: bezafibrate 400 MG
DrugBank: Bezafibrate (DB01393)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg SR tablet of Bezafibrate once daily for the remainder of the study
Study: NCT04594694
Drug: Bezafibrate 400 mg Placebo
Normalized name: bezafibrate 400 MG
DrugBank: Bezafibrate (DB01393)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet daily for the remainder of the study
Study: NCT04594694
Drug: OCA
Normalized name: DOCA
DrugBank: Desoxycorticosterone acetate (DB06780)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: OCA one tablet will be administered.
Study: NCT04594694
Drug: Bezafibrate
Normalized name: bezafibrate
DrugBank: Bezafibrate (DB01393)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bezafibrate one tablet will be administered.
Study: NCT02760407
Drug: Olokizumab 64mg q4w
Normalized name: olokizumab
DrugBank: Olokizumab (DB13127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 mg/mL sterile solution for SC injection in a 2 mL clear Type I glass vial
Study: NCT02760407
Drug: Olokizumab 64mg q2w
Normalized name: olokizumab
DrugBank: Olokizumab (DB13127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 mg/mL sterile solution for SC injection in a 2 mL clear Type I glass vial
Study: NCT02760407
Drug: Adalimumab 40mg q2w
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 0.4 or 0.8 mL prefilled, single-dose syringe
Study: NCT00673673
Drug: bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: bevacizumab will be used at a dose of 10 mg/kg administered every 2 weeks on day one of FOLFOX chemotherapy
Study: NCT01664845
Drug: metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: metformin 500mg tid
Study: NCT01664845
Drug: pegylated-IFN
Normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: pegasys 180 mcg qw
Study: NCT01664845
Drug: ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ribavirin 800-1200 mg qd according to BW
Study: NCT01111825
Drug: Temsirolimus
Normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 28 day treatment cycle Phase 1~* Weekly intravenously (IV) on days 1, 8, 15, and 22~* Starting dose 8 mg IV weekly (dose level 1). Three patients initially enrolled in each cohort~Phase 2~* Dose escalation cohort - 8 mg IV weekly on Days 1, 8, 15, and 22, and then 15 mg IV weekly starting on Day 29~* HER2-amplified and Triple negative - 8 mg IV weekly on Days 1, 8, 15, and 22
Study: NCT00018863
Drug: Methylphenidate
Normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00945191
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 175 mg/m\^2 IV infusion once every 3 weeks (1 cycle) for 6 cycles
Study: NCT00945191
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin (target area under the concentration versus time curve of 6.0 mg/mL/min using the Calvert Formula) IV infusion once every 3 weeks (1 cycle) for 6 cycles
Study: NCT00836823
Drug: Alfuzosin
Normalized name: Alfuzosin
DrugBank: Alfuzosin (DB00346)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alfuzosin 10mg once daily for 12 months
Study: NCT01475292
Drug: RV568
Normalized name: Ravulizumab
DrugBank: Ravulizumab (DB11580)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: RV568 50 ug administered via a nebuliser once daily for 14 days
Study: NCT01475292
Drug: RV568
Normalized name: Ravulizumab
DrugBank: Ravulizumab (DB11580)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: RV568 100 ug administered via a nebuliser once daily for 14 days
Study: NCT03399110
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oxaliplatin 130 mg/m2
Study: NCT01111825
Drug: Neratinib
Normalized name: NERATINIB
DrugBank: Neratinib (DB11828)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 28 day treatment cycle~• 240 mg orally daily
Study: NCT03048097
Drug: Rubidium
Normalized name: rubidium
DrugBank: Rubidium (DB11346)
Approvals — FDA: no, EMA: no, PMDA: no
Description: used in PET scans
Study: NCT01151670
Drug: pioglitazone
Normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pioglitazone 22.5 mg daily before, during and after radiation therapy.
Study: NCT01151670
Drug: Pioglitazone
Normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pioglitazone 45 mg by mouth daily before, during and after radiation therapy
Study: NCT04001829
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT04001829
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT00086346
Drug: Sirolimus (Rapamune)
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00086346
Drug: Cyclosporine or Tacrolimus
Normalized name: Tacrolimus
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00353704
Drug: pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: capsule 150 mg x 1 per orally one hour before surgery
Study: NCT00353704
Drug: morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients were equipped with a PCA (patient controlled analgesia) for 24 hours after surgery. The sum of morphine used was registered (milligram).
Study: NCT04495374
Drug: Pregabalin 300mg
Normalized name: PREGABALIN 300MG CAP,ORAL
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Group P1 will receive a 300 mg tablet of pregabalin, 02h before the surgical procedure
Study: NCT00898716
Drug: BMS-754807
Normalized name: BMS-754807
DrugBank: BMS-754807 (DB15399)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, Oral, 20 mg, 30 mg, 50 mg, 70 mg, 100 mg, 130 mg, 160 mg, 200 mg once daily, 3-5 months, depending on response
Study: NCT02406872
Drug: Remimazolam Tosilate
Normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV pumping for anesthesia
Study: NCT02406872
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV bolus for anesthesia
Study: NCT05134298
Drug: Piperacillin/tazobactam, Meropenem
DrugBank: Piperacillin (DB00319)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This is an observational study exploring the antibiotic plasma concentration profiles in ICU paitents after the first drug administration.
Study: NCT02613572
Drug: alpha lipoic acid
Normalized name: Alpha lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00394914
Drug: Pleconaril
Normalized name: pleconaril
DrugBank: Pleconaril (DB05105)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pleconaril nasal suspension is supplied in a bottle containing 120 actuations. Each actuation contains 1.5 mg of pleconaril.